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Glossary  
 
 
BMI   Body Mass Index; weight (kg), divided by height (metres) squared 
BC   Breast Cancer 
CT   Computed Tomography 
COPD   Chronic Obstructive Pulmonary Disorder 
ECOG    Eastern Cooperative Oncology Group 
EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire 
EWGSOP  European Working Group for Sarcopenia in Older People 
FFM   Fat Free Mass 
FFMI   Fat Free Mass Index 
FM   Fat Mass 
FMI   Fat Mass Index 
MST   Malnutrition Screening Tool 
mTOR   Mechanic Target of Rapamycin (signalling pathway) 
PF   Physical Function 
PG-SGA  Patient Guided Subjective Goal Assessment 
QOL   Quality of Life 
RCT   Randomised Control Trial 
R.V.   Reference Values 
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PART 1.0 Introduction 
Breast cancer (BC) is one of the most studied malignancies in the world [1], and for good reason;  it 
affects 1 in every 8 women in Australia, is the most common form of cancer amongst women [2], and is 
considered one of Australia’s largest health burdens [3]. In Australia, early-stage BC 5-year survival rates 
are approximately 90%; however, 1 in 20 women whose disease is confined to the breast, and 1 in 6 women 
whose BC has reached adjacent tissue, will eventually progress to metastatic disease [4]. Five-year survival 
rates of advanced disease drop to only 40% in Australia [5]. 
Epidemiological studies have shown higher incidences of BC in those who are overweight or obese 
when compared to those of a healthy weight [6]. Obesity indicates a high percentage of body fat which has 
previously been an important predicting factor for both cancer incidence, and prognostic outcomes; however, 
emerging research suggests that fat free mass (weight the of body excluding weight of fat [7]) is a greater 
predictor of prognostic outcomes [8]. 
Apart from obesity being a risk factor for BC, it is common for women with BC to experience a loss 
in muscle mass, and/or gain in fat mass post diagnosis [8, 9]. Weight gain in patients with BC, particularly 
those who are premenopausal or undergoing chemotherapy, is a phenomenon that has been reported since 
1978, and in 2001, Demark-Wahnefried et al reported that weight gain during adjuvant chemotherapy was 
associated with decreased muscle mass and an increase in fat mass simultaneously (sarcopenic obesity) [10, 
11]. Sarcopenic obesity is associated with poorer prognostic outcomes [8, 9].  
Despite the abundance of research in early stage BC, little is known of the effects of chemotherapy 
on body composition in patients with metastatic BC. To our knowledge, the only study investigating body 
composition changes in patients with metastatic BC was conducted by Rier et al in 2017. This retrospective 
study reviewed 98 patients with metastatic BC from 2000-2006, and found through their routine pre- and 
post-treatment CT scans that, the quality of muscle (muscle attenuation) decreased with paclitaxel 
chemotherapy treatment, while adiposity and muscle mass remained stable [12]. An unpublished systematic 
review exploring exercise interventions for metastatic patients with BC has found a total of seven 
Randomised Control Trials (RCTs), however none of these studies included body composition as an 
outcome [13].  
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With little known about the metastatic BC population, current practice for this population group is 
not influenced by high quality, recent evidence; therefore, limiting optimal outcomes for patients with 
metastatic BC. The current research study aims to investigate the effects of chemotherapy on body 
composition and physical function in women with metastatic BC.  
This thesis includes 4 chapters; the current introduction, a review of literature, a research study 
manuscript, and conclusions and recommendations. These chapters will provide insight into the purpose of 
this research; explore current literature and associated gaps with a literature summary matrix table available 
in Appendix A; as well as a  detailed research study; preliminary results; and future recommendations. 
The current chapter highlights the importance of research in this area of metastatic BC. The following 
chapter summarises the available research on body composition and BC, explores changes in body 
composition during treatment and how that may affect physical function, outcomes, and prognosis. The third 
chapter will include the preliminary results of the research study, while the final chapter will 
explore future recommendations based on the previous chapters in this thesis.  
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PART 2.0 Literature Review 
2.1 Breast Cancer  
2.1.1 Prevalence and Outcomes of Cancer  
Cancer is the second highest contributor to non-communicable disease deaths worldwide, and 
in 2018, 138,321 new cancer diagnoses are expected in Australia [1, 14]. Not only is cancer one of 
Australia’s leading causes of death, but the social and economic burden to individuals, families, and 
communities is considerable [15].   
In women, Breast Cancer (BC) is the most common type of cancer. BC contributes to approximately 
25% of all cancer cases world-wide, and while both males and females are affected by BC, being female is 
the single biggest risk factor to developing the disease [8, 9]. Next to this, an increased age, significant 
family history or genetic predisposition to BC, and being overweight or obese are also strong risk factors [9]. 
There are several stages of BC which influence treatment plans, and prognosis [4]. Early stage BC 
describes tumours that are no more than  two centimetres and have not spread to the surrounding tissue or 
lymph nodes; locally advanced BC describes tumours that have spread beyond the breast to surrounding 
tissue or lymph nodes surrounding the breast [4]. Metastatic BC is defined as when the disease is no longer 
localised to the breast, and has spread to other organs in the body [9]. Often, metastatic disease 
affects women who have had a previous diagnosis of BC, however for some women, it may be 
their first diagnosis[4, 5]. 
While BC is a highly prevalent disease, with treatment, there is also a high survival rate for primary 
stages of the disease [8]. Five-year survivorship rates of primary BC are approximately 90% in Australia, 
and have improved from 72% in the 1980’s [8]. Despite this, the rate of women in Australia who survive at 
least five years post metastatic BC diagnosis is 40% as of 2016 [8]. In general, higher survival rates are more 
common in higher-income countries where prevention measures such as early screening, and well-
established treatments are accessible [8], however the patient’s quality of life varies based on a number of 
influencers such as age, partnership status, and financial resources [16]. 
Having a high incidence within many communities around the world, it is clear why BC is one of the 
most studied malignancies [8]. However, despite the abundance of research that is available for primary BC, 
a recently conducted systematic review found only 7 papers investigating physical exercise interventions in 
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the metastatic BC population and no studies investigating nutrition interventions [13]. This review reinforces 
the gap in knowledge surrounding body composition and associated impacts for this population. 
 
2.1.2 Treatment, Associated Symptoms and Effects on Body Composition 
 
 Treatments for BC differ depending on the progression of the cancer, the individual’s overall health, 
age, the molecular make-up of the individual tumour, and gene expression. Treatments can include one of, or 
a combination (adjuvant) of surgery, radiation therapy, chemotherapy, or hormone therapy [4]. Treatment 
goals for primary BC (early stage to locally advanced) are to eradicate the tumour and prevent it from 
returning; whereas the goal for treating metastatic BC is to maintain quality of life, prolong life, and to 
reduce symptoms and pain [4].  
 Treatments often coincide with related side effects, and depending on the individual, type, and 
duration of treatment, side effects may be chronic and/or acute, however this varies with each treatment and 
each individual patient [17]. Common short-term side effects of chemotherapy can include anything from: 
nausea; fatigue; decreased immune function; pain; neuropathy; dry mouth; vomiting; metabolic, 
psychological and emotional disturbances; hair loss, dyspnoea, mucositis, diarrhoea, muscle weakness, 
osteoporosis, and/ or wound infection [4]. Similar symptoms present with radiotherapy and vary depending 
on the location of radiation; skin irritation, dryness, itching, blisters, and peeling; fatigue; scarring of organ 
tissues and joint stiffness are general side effects of radiotherapy [17, 18]. Possible side effects from surgical 
treatment include pain, discomfort, wound infection, bleeding, lymphedema, and or blood clots; 
complications during surgery are often minor and are easily treated [17, 18]. These treatment-related side 
effects may cause altered eating habits, which may contribute to either weight gain or loss, influencing 
changes in overall body composition [17]. While chemotherapy-related side-effects are often only 
experienced during treatment, some patients may suffer from long-term side-effects [19]. Certain 
chemotherapy drugs may cause long term damage to organs such as the lungs, or heart, and cause fatigue, 
low immunity, and/or infertility in some patients [19].  
 The most common drugs used for metastatic BC are either anthracycline- or taxane-based for 
palliative intent [20]. These treatments may lead to side-effects such as nausea, vomiting, diarrhoea, and 
anorexia (loss of appetite) [20]. Additionally, anthracycline- and taxane-based treatments have been 
associated with a decline in muscle quality [12], however only one known human study investigated the 
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changes in body composition with anthracycline- and taxane-based treatments in metastatic BC. Therefore, 
further research on the effects of chemotherapy on muscle quality is required.  
2.2 Body Composition and Physical function 
2.2.1 Outcomes Influenced by Body Composition 
Traditionally, the weight to height ratio, also called Body Mass Index (BMI) has been a common 
tool used to aid in calculating risk for chronic disease [21], however, body composition may give a clearer 
understanding of someone’s health outcomes when compared to BMI [22]. Body composition refers to the 
percentages of fat mass, lean body mass, and bone in an individual’s body [23]. An unfavourable body 
composition aligns with a high body fat percentage, and/or low lean body mass percentage, with or without 
the presence of a high BMI [24]. High body fat percentage and low lean body mass, also called sarcopenic 
obesity, is associated with cancer risk and tumour progression [25, 26]; and while this is not completely 
understood, mechanisms involving chronic inflammation, insulin resistance, low adiponectin levels, and 
increased endogenous sex steroids associated with a high body fat are the most studied [25, 26].  
In addition to cancer risk and tumour progression, a low muscle mass is associated with further 
adverse outcomes such as increased falls risk, poor physical function, and negatively impacting quality of 
life in older populations with age-related decreased muscle mass [27]. A strong association with physical 
disability (loss in physical function and declined muscle strength) has been observed in participants with a 
muscle mass at least two standard deviations below the relevant reference cut offs [27]. While the 
associations between a decreased muscle mass is well established, it is becoming increasingly recognised 
that a decrease over time in muscle mass is a greater predictor of future outcomes when compared to muscle 
mass alone [27].  
2.2.2 Body Composition and Cancer 
It is not uncommon for patients with BC to experience changes to their body composition post 
diagnosis [11]. Patients undergoing adjuvant chemotherapy commonly experience treatment-related 
symptoms of loss of appetite, nausea, and vomiting which are often associated with weight loss [18]. Dixon 
et al  first observed a unique change in body composition of patients with BC in 1978, whereby 
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patients would gain weight despite experiencing nausea and vomiting [10, 28]. In the years following 
Dixon et al  , weight gain in the BC population became a common observation, with weight gain ranging 
between 2.5 - 6.2kg in 12 months [10, 28, 29].  
Adjuvant chemotherapy associated weight gain has previously been attributed to a positive energy 
balance (state of which the body has gained more energy than it has spent) [10]. However, recent studies 
have shown that there are more factors other than positive energy balance, which affect weight gain in this 
population, such as insulin resistance; physical inactivity (regardless of energy intake); and menopause-like 
hormonal changes that impact fat metabolism [10, 30]. Although there is limited research, evidence suggests 
that patients with BC either gain fat mass, lose lean body mass, or experience both during adjuvant 
chemotherapy treatment [10].  
Demark-Wahnefried and colleagues observed weight changes in 60 patients with BC (n=38: 
adjuvant chemotherapy, n=22: localised treatment) at four time points (baseline, 2 months, 6 months and 12 
months) and assessed weight, body composition, resting energy expenditure, physical activity, energy intake, 
and monthly 2-day dietary recalls [10]. Findings highlighted that a decrease in physical activity as the most 
likely factor contributing to adjuvant chemotherapy weight gain, and that weight gain can occur either with 
or without lean tissue loss [10].  
Contrast to Demark-Wahnefried et al’s findings, Kutynec et al  found only small shifts in 
body composition over 12 weeks (-0.4kg LBM, + 1.3kg FM) in both localised treatment (n=10) and 
adjuvant chemotherapy (n=8) treatment groups [31]. As this study followed up after only 12 weeks, it is 
likely that larger body composition shifts would be observed after a longer time period.   
The aforementioned studies have been researching early stages of BC. Further research is required, 
as there is no research currently investigating these relationships in the metastatic BC population. 
2.2.3 Breast Cancer and Body Composition Changes: influence on outcomes 
Weight gain in women with BC may have many physical, social, emotional and psychological 
impacts [10] that has been reported as “distressing” by some patients [11]. For some patients, increased 
weight not only impacts one’s quality of life, it affects the individual’s general health, and prognostic 
outcomes [32].  
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Weight gain and adiposity has been associated with increased mortality and disease recurrence in 
women with early stage BC [33, 34], while also increasing risk of obesity related complications such as 
diabetes, hypertension, and cardiovascular or gall bladder disturbances [10].  
 
2.3 Sarcopenia  
 
2.3.1 Definitions of sarcopenia 
 
 Sarcopenia is an age-related involuntary loss of skeletal muscle mass associated with loss of 
physical function, frailty, and disability [35, 36]. The condition is most common amongst individuals over 80 
years of age, and affects approximately 20% of individuals over 60 [37]. These percentages however, are 
likely to be underestimated as participation of frail or institutionalised individuals in these age groups is 
often low in clinical trials [37]. Age-related loss in muscle mass is the primary cause of sarcopenia in 
geriatric populations [22], however suboptimal diet, bed rest, sedentary lifestyle, chronic diseases, and 
medications or treatments will also influence the progression of sarcopenia regardless of age [22, 36].  
It is common to see an age-related gain in fat mass in combination with a decline in muscle mass, 
however this shift in body composition may also be influenced by aforementioned factors. A body 
composition of low muscle mass and high fat mass in the presence of decreased muscle strength and/or 
physical function is known as sarcopenic obesity [38]. Sarcopenic obesity can occur in the presence of a 
high, normal, or low BMI, and is of greater concern than sarcopenia without obesity, as it has been found to 
be associated with poorer muscle quality (ratio between muscle quantity and strength) and strength [38]. A 
study exploring the force per unit of cross-sectional muscle area in obese elderly, non-obese frail, and normal 
weight, non-frail participants found that although obese elderly participants had the highest quantity of 
muscle, they had the poorest muscle quality when compared to other participant groups [38]. In the same 
study, obese elderly participants also had reduced functional status, aerobic capacity, walking speed, balance, 
and strength when compared to other participants [38, 39]. 
While no broadly accepted clinical definition exists for sarcopenia, the European Working Group on 
Sarcopenia in Older People (EWGSOP) recommends using the presence of both low muscle mass and low 
muscle function (muscle strength or physical function) for the diagnosis of sarcopenia [22]. Sarcopenia is a 
condition that has many attributing causes and outcomes, and is recognised as a multi-faceted condition with 
varying levels of severities and relative disease stages[22, 36]. The EWGSOP has developed conceptual 
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stages of sarcopenia to aid in diagnosing disease severity (Table 1) [22]. Conceptual staging of disease can 
guide clinical management and treatment of sarcopenia, and may assist future research studies [22]. 
Table 1: Conceptual stages for sarcopenia [22] 
Stage Muscle mass Muscle strength Physical function 
Presarcopenia ¯   
Sarcopenia ¯ ¯ Or ¯ 
Severe sarcopenia ¯ ¯ ¯ 
 
Defining reference values for sarcopenia depends on measurement techniques, equipment, and 
availability of reference studies. The EWGSOP recommends using normative (healthy young adult) data 
over predictive populations with cut-offs at 2 standard deviations below the mean reference value [22]. This 
being said, the majority of studies that have been used to develop reference values lack ethnic diversity and 
include mostly Caucasian participants [40]. Further research involving world-wide populations and 
ethnicities is required to obtain more accurate reference values [40].   
 
2.3.2 Sarcopenia and Cancer 
 
 While weight gain has traditionally been a predictor for disease outcomes in BC, emerging evidence 
exploring the relationship between fat and lean body mass has highlighted the importance of skeletal muscle 
stores in improving cancer outcomes [41]. In cancer patients, low lean body mass, or sarcopenia, is 
associated with treatment failure, increased chemotherapy toxicity, and overall survival irrespective of 
adiposity [41]. A systematic review investigating the prevalence of pre-therapeutic sarcopenia in cancer 
patients found that sarcopenia was present in 38.6% of 6894 participants, and was significantly and 
independently associated with post-operative outcomes, chemotherapy related toxicity, and reduced survival 
[42]. 
In 2009, Prado and colleagues found sarcopenic patients with metastatic BC had increased 
chemotherapy toxicity (p=0.04), and shorter time to tumor progression when compared to their non-
sarcopenic counterparts (62 days and 105 days respectively) [24]. These findings were supported by 
additional studies exploring the same outcomes in cancer patients [43, 44]. 
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Recently, sarcopenic obesity has been associated with worse clinical outcomes for cancer patients 
[45]. A review of 14 studies involving clinical outcomes of sarcopenic obesity in cancer patients found that 
sarcopenic obesity was highly prevalent amongst the cancer population, and negatively affects prognosis 
[45]. The included studies in the review had heterogeneity in methods to categorise sarcopenia, therefore 
limitations apply; nevertheless, results showed that sarcopenic obese participants had an increased chance of 
postoperative complications (5-fold increase), poor functional status (47% of sarcopenic obese participants 
opposed to 27% non sarcopenic obese), and shorter survival (11.3 months opposed to 21.6 months in obese 
participants with normal muscle mass) when compared to non-sarcopenic obese participants [45].    
2.4 Exercise in Cancer 
2.4.1 Background, Current Research and Guidelines 
Exercise has proven to be an integral part of a healthy lifestyle and if practiced regularly, is able to 
alter one’s body composition by increasing muscle mass and reducing fat mass [46]. In cancer, it has 
now been well documented that exercise interventions are safe, improve physical function, disease 
outcomes and overall quality of life through an increase in muscle mass [47].  
A systematic review and meta-analysis investigating the effects of resistance training exercise on 
muscular strength in cancer patients undergoing treatment found that resistance exercise was effective in 
improving lower-limb muscle strength, maintaining lean body mass, and reducing body fat; 
supporting resistance training exercise [48]. In BC however, Holmes et al  reported that aerobic exercise 
training in women with primary BC had a protective association: women in the study who exercised 
greater than nine hours each week had reduced risk of recurrence, cancer-related mortality, and 
overall mortality [49]. Courneya and colleagues investigated the effects of aerobic exercise training and 
resistance training exercise in patients with BC undergoing adjuvant chemotherapy. Results from this 
study found that resistance training exercise was superior to usual care and improved self-esteem, 
muscular strength, lean body mass percentage, and chemotherapy completion rates [50]. While there 
were positive changes in quality of life, fatigue, depression and anxiety in both aerobic and resistance 
training exercise groups compared to usual care, these outcomes did not reach statistical significance [50]. 
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 Currently, general recommendations suggest that cancer patients participate in 30 minutes of 
moderate exercise (either resistance or aerobic), 5 days a week (150 minutes per week) [51]. These 
recommendations are based on research showing improvements in mood, fatigue, and osteoporosis with 
exercise, as well as favourable survival outcomes and lower rates of adverse side effects [51, 52]. This guide 
to exercise is a general recommendation and will depend on individual circumstances, in which case, varying 
recommendations may be offered [51].  
 
2.4.2 Exercise for Sarcopenia in Cancer 
 
Several studies have investigated age-related sarcopenia, and interventions to delay disease 
progression and/or improve muscle mass by applying exercise interventions.  
Exercise interventions for sarcopenia in older adults have proved beneficial and were reviewed by 
Taffe in 2006 [37]. Taffe noted that numerous studies [53, 54] demonstrated that resistance exercise training 
amongst older men and women improved muscle cross sectional area, and muscle strength significantly 
(>100%) when participating in a resistance exercise intervention for 12 weeks [54]. A systematic review of 
low-quality randomised controlled studies investigating exercise, dietary, and drug interventions for treating 
sarcopenia alone, found that 3 months of resistance exercise interventions (2-3 times per week) may play a 
role in improving muscle mass, muscle strength, and walking speed in older individuals with sarcopenia 
[55].  
Limited studies have been conducted investigating exercise interventions specifically for cancer 
patients with sarcopenia. However, a RCT conducted in 2012 investigated the impact of resistance and 
aerobic exercise training on sarcopenia, and dynapenia (reduced strength) in patients with BC receiving 
adjuvant chemotherapy [53]. The study reported that resistance training exercise was superior to usual care 
in improving sarcopenia-related outcomes, and when compared to aerobic exercise training and usual care, 
resistance exercise training was superior in reversing sarcopenia [53]. More research on the effectiveness of 
exercise interventions in sarcopenic patients with metastatic BC is required.  
 
2.4.3 Barriers to Physical Exercise 
 
 The profound improvements that exercise has on muscle hypertrophy and strength, particularly with 
resistance exercise training, are well known, however barriers to physical exercise still exist within both 
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healthy and unwell populations. A 2012 survey conducted by the British Heart Foundation found that the 
most common barriers to exercise for UK healthy adults were work commitments (45% men, 34% women), 
and time (38% men, 37% women) [56]. Despite evidenced-based guidelines and well supported positive 
outcomes, cancer patients are not meeting the recommended amount of physical exercise, and are therefore 
not experiencing the potential benefits of exercise. A study conducted in 2014 in the UK observed the 
physical activity levels and barriers to exercise in 114 patients with either bowel, breast, or prostate cancer. 
The authors found that 76% of patients did not meet exercise guidelines of 150 minutes per week, and of 
those patients eligible for exercise referral, 44% refused. The main barriers to physical exercise in these 
patients were health concerns (32%) and time (27%) [52].  
A RCT explored the change in patient-perceived exercise barriers in prostate and breast cancer 
survivors at baseline, and after 1 year of being on a home-based exercise and healthy eating intervention 
[57]. At baseline, 52% of participants with BC and 45% of participants with prostate cancer reported “too 
busy” as the top barrier to exercise, while “no willpower”, and “don’t like exercising in bad weather” were 
also in the top three reported barriers  [57]. At 1 year, the number of participants recording these barriers had 
reduced by 37% and 36% in the breast and prostate cancer survivor populations respectively [57].  
A 2014 study focus group investigated factors that influenced exercise adherence in patients with BC 
and highlighted both internal and external barriers to exercise in this population [58]. The study involved 27 
patients with BC in a home-based exercise program that combined both resistance and aerobic exercises. 
Participants were also asked questions on their perceptions and experiences in engaging with the exercise 
program to explore barriers and adherence. Valuing other activities over exercise, and treatment side-effects 
were the two barriers that were highlighted by the focus group [58]. Participants also expressed that their 
desire to restore normality in life, constructive support during exercise, and the positive outcomes that come 
with exercise as motivators to participate in the exercise program [58]. In conclusion, time, and health 
concerns are reoccurring barriers to physical activity in the BC population; this may be due to limited 
education regarding the positive outcomes of exercise during treatment, and poor access to exercise 
programs for this population.  
 
 
17 
2.5 Dietary Interventions for Cancer and Sarcopenia 
2.5.1 Diet, Muscle Growth and Maintenance 
Muscle maintenance and growth can only occur if muscle protein synthesis occurs at a greater rate 
than muscle protein breakdown; this requires a positive protein balance and results in higher muscle tissue 
turnover [59]. Dietary protein is essential for muscle maintenance as it provides amino acids that are required 
for muscle protein synthesis. Exercise with reduced protein intake results in a negative protein balance, 
which causes muscle catabolism [60]. Maintenance of muscle requires a balance of anabolic and catabolic 
states within the muscle tissue, a balance that, with age, favours muscle breakdown [61, 62]. In sarcopenia, 
there is a decreased sensitivity of protein synthesis, and a loss of physiological concentrations of amino acids 
due to a lack of cell-signalling pathway (mTOR) activity, which causes a negative protein balance and 
muscle loss [60].  
 2.5.2 Current Research on Diet, Sarcopenia, and Cancer 
Dietary intervention studies for sarcopenia in patients with cancer is not well documented. A 
systematic review by Yoshimura et al suggests that although this is based on low-quality evidence, 
nutritional intervention through essential amino acids, collagen peptides, protein, Vitamin D,  beta-hydroxy-
beta-methylbuterate, leucine, branched-chain amino acid, creatine and tea catechin supplements (not 
combined) may play a role in improving muscle strength over 3 months of intervention in patients with 
cancer? [55].  
A systematic review investigating the use of nutritional, vitamin and mineral supplements as 
treatment for cachexia in cancer patients evaluated 21 papers [63]. The review found that vitamin D and 
vitamin C (oral and intravenous (IV)) supplementation improved muscle strength, and physical and cognitive 
domains of quality of life in cancer patients [63]. In terms of protein and dietary supplements, three studies 
observed positive effects on weight gain of combining arginine, glutamine, and beta-hydroxyl beta-methyl 
butyrate [63].  
In summary, while research in the domain of dietary supplementation is limited in sarcopenic and 
cachexic cancer populations, some promising results highlight the need for further investigation into these 
relationships to improve current guidelines.  
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2.5.3 General Nutrition Guidelines for Cancer Patients  
 
Previous research exploring diet and exercise in cancer patients has led to a set of lifestyle 
recommendations for cancer patients. The 2012 Australian evidence-based practice guidelines for patients 
receiving chemotherapy and/or radiation therapy suggest dietetic interventions (nutrition counselling, and /or 
supplements) to increase dietary intake and weight, but have little effect on patient-centered outcomes such 
as quality of life, physical function, and patient satisfaction [64]. In patients receiving radiation, aiming for at 
least 125kJ/kg/day and 1.2g/protein/kg/day was recommended [64]. Chemotherapy patients have effective 
results of improved dietary intake and weight through standard nutrition counselling and/or oral nutritional 
supplements [64]. 
 The 2017 ESPEN guidelines on nutrition for cancer patients recommends that cancer patients have 
their nutrition status monitored regularly, with quantitative and objective measures of nutritional intake taken 
[65]. For patients with advanced/metastatic cancer, the ESPEN guidelines strongly recommend to routinely 
screen for adequate nutrition intake, and to tailor nutrition interventions if needed with the patient to consider 
disease progression, quality of life, and patient burden [65].  
 
 
2.6 Conclusion of Literature 
 
A thorough and critical exploration of the available literature highlights the knowledge gaps for 
exercise and nutrition in the metastatic BC population. Intervention studies involving early-stage BC 
populations and sarcopenic populations have proven exercise is beneficial for improving muscle quality, 
muscle strength, and physical function – therefore improving overall quality of life and outcomes. We also 
know there is evidence showing the benefits of nutritional counselling and supplements to improve muscle 
mass, however no clinical studies have been published investigating a combined nutrition and exercise 
intervention in metastatic BC. Further research into whether exercise has the same benefits in the metastatic 
BC population, in combination with nutrition interventions will provide evidence-based practice guidelines 
to enhance quality of life for these patients.  
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3.1 Abstract 
 
 
Background:  
The current scope of literature exploring body composition changes during chemotherapy has primarily been 
investigated in patients with early-stage (I-III) breast cancer (BC), with little known in patients with metastatic BC. A 
higher fat free mass index (FFMI) has been associated with improved treatment outcomes, survival, and quality of life 
in cancer patients. With the known benefits of a high FFMI in cancer populations, this study aims to describe changes in 
body composition, muscle strength, and physical function during chemotherapy in the metastatic BC population to 
inform future intervention studies for the improvement in overall quality of life. 
 
Methods: 
 This was a 6-week prospective observational cohort study where we measured changes in FFMI, muscle 
strength, and physical function in patients with metastatic BC during chemotherapy. Quality of life, protein intake, 
physical activity, and malnutrition status were also measured. Values were compared to reference values (where 
applicable age- and gender specific). 
 
Results: 
 Five participants were enrolled in the study, and three completed all measurements. Preliminary results did not 
indicate sarcopenia in any of the participants, however at baseline 3 participants were overweight or obese, median 
protein intake in all participants was below recommended intakes (75%), and 4 participants did not participate in the 
recommended amount of physical activity. Physical function did decline with time in 2 participants, and muscle 
strength remained stable in three participants that completed the study.  
 
Conclusions: 
 From the preliminary data collected, our sample size reflects similar trends to those highlighted in early-stage 
BC populations. Most of our participants were overweight or obese, the median protein intake was inadequate, and 
participants did not participate in sufficient physical activity. Additional recruitment is required to confirm these trends 
in the metastatic BC population.  
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3.2 Introduction 
Breast cancer (BC) is the most common type of cancer diagnosed in women, with approximately 8.2 million 
diagnoses of BC globally in 2012 [66]. Evidence suggests that patients with cancer typically experience involuntary 
weight loss due to treatment side-effects; however, patients with early stage (I-III) BC are more likely to experience a 
gain in fat mass, which in some cases, is accompanied by a simultaneous loss in muscle mass [67]. Low muscle mass in 
combination with a loss in function and, or muscle strength is known as sarcopenia [22]. This reduction in muscle mass 
in the presence of higher fat mass is known as “sarcopenic obesity” and may occur with or without the presence of a 
high body mass index (BMI) [68].  
While obesity is generally considered a major body compositional predictor for poor health and disease 
prognosis, recent evidence suggests that a loss of muscle mass in the presence of a high fat mass is a greater predictor 
for negative health outcomes in both healthy, and cancer populations [22, 69, 70]. Sarcopenia is usually a chronic 
condition related to either age, lack of physical activity, nutrition (insufficient protein intake), or disease (for instance 
individuals with cancer, chronic obstructive pulmonary disorder (COPD), or chronic heart failure) and is accompanied 
by a decline in physical function and/or loss of muscle strength [22, 68, 71]. The decline in physical function and 
strength associated with sarcopenia affects an individual’s independence, mobility and nutrition status [22, 68].  
Body composition has been shown to influence not only BC risk, but also outcomes post treatment [70]. 
Whilst findings are unclear on exact numbers, moderate increases in dietary protein for elderly people with sarcopenia 
have been shown to improve lean body mass, strength and physical function [72-74]. This could be either achieved by 
protein intakes above the recommended intake or supplementation of amino acids or protein. 
For muscle mass and physical function maintenance, general recommendations for patients undergoing cancer 
treatment are to consume sufficient dietary protein (> 1.2g/kg (adjusted) body weight [75]) and to participate in 
physical activity [65, 76, 77]. While the benefits of exercise therapy for both sarcopenia and cancer are well explored to 
help preserve muscle mass; reduce fat mass and treatment side-effects; and  improve strength, self-esteem, and 
overall quality of life [78, 79], the large majority (40-80%) of patients with BC or survivors are not meeting 
recommended physical activity levels [80-86]. In addition, BC survivors are unlikely to be meeting the 
recommended amount of dietary protein [87], however there is currently no data on physical activity levels and 
protein intake in the metastatic population. Moreover, research investigating body compositional changes in patients 
with BC exists primarily in early-stage BC, and there is currently no research investigating chemotherapy effects on 
body composition in the metastatic population.  
Further research investigating body composition and chemotherapy in patients with metastatic BC is needed to 
provide evidence-based recommendations to improve physical function, strength, and overall QOL for this patient 
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group. The aim of this observational cohort study was to investigate the effects of chemotherapy on body composition, 
physical function and muscle strength in adult patients with metastatic BC in Australia. We also explored the 
relationship between body composition, physical function, and muscle strength. These aims were to inform future 
intervention studies for this population group.  
 
3.3 Methods 
 
3.3.1 Study Design 
 
This prospective observational cohort study was reported according to the STROBE guidelines. Participants 
undergoing chemotherapy for stage IV BC were recruited upon enrolment of chemotherapy (Baseline: Cycle 1, Day 1 
(C1D1), of chemotherapy), and assessed again at 3 weeks and at 6 weeks. A detailed time-line of the project is 
presented in Appendix B. 
 
3.3.2 Eligibility criteria and recruitment 
 
To be included in the study, participants were required to meet the following criteria; female; above 18 years 
of age; metastatic BC disease (primary); life expectancy greater than 3 months; mobile; ECOG performance status of 
0,1, or 2 (confirmed by the participant’s oncologist) [88]; commencing C1D1 of chemotherapy for metastatic BC where 
minimum 2 cycles of chemotherapy were scheduled; and able to speak, read and write English. Participants were to be 
excluded if they had a permanent pacemaker or other medical implant not appropriate for BIA assessment; severe 
cognitive, intellectual disability or mental illness; presence of acute illness or unstable chronic illness; or any other 
condition that would interfere with the study or safety of the patient according to the PI, nurse, or patient.  
Participants were recruited from oncologist, nursing staff, and cancer care coordinator referrals at the Mater 
Cancer Care Centre (MCCC). The primary researcher (AB) would review upcoming appointments in the chemotherapy 
treatment scheduler system to acquire any potential participants, and confirm appropriate eligibility with oncologists 
and/or cancer care coordinators. The study was also announced by study flyers in waiting areas. Those who were 
interested in participating were screened for eligibility through inclusion and exclusion criteria. Of the 10 participants 
approached for the study, 5 were excluded and reasons for exclusion were recorded. Reasons for exclusion included 
English as a second language, did not wish to participate, did not classify as metastatic disease, and having already 
surpassed C1D1) of their chemotherapy. Participants that were eligible received a written and verbal explanation of the 
study by the PI or student investigator before consent was obtained. This study was approved by the Human Research 
Ethics Committee of Mater Research and Mater Research Governance (HREC/17/MHS/63) (Appendix C).  
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Figure 1 Flow chart of study recruitment 
 
3.3.3 Participant Descriptive Characteristics 
 
After written consent was obtained, the primary investigator recorded age, smoking status, and ethnicity of the 
participant during a face-to-face interview at the MCCC. Medical history, treatment regimen, and stage of disease were 
obtained from the participant’s medical records. All information recorded was de-identifiable on the approved CRF, and 
then recorded into the database. Participants then completed baseline measurements on C1D1 of their treatment. 
Measurements involved anthropometric measures, body composition, muscle strength, physical function, dietary intake, 
and quality of life as described in Sections 3.3.4 to 3.3.6, and 3.3.9. Malnutrition and sarcopenia status were classified 
for participants post data collection as described in Sections 3.3.7 and 3.3.8. 
 
3.3.4 Anthropometry  
 
Height was recorded at baseline with each participant having taken their shoes off, arms hanging freely by 
their sides, using a stadiometer (Wedderburn WM303H, Willawong, QLD, Australia); measurements were rounded to 
the nearest 0.5cm and recorded in meters. Participants were weighed without shoes on calibrated scales at each time 
point in the study. Weight on a digital scale (Wedderburn WM303H, Willawong, QLD, Australia) was recorded to the 
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nearest decimal in kg and the participant’s BMI at each time point was calculated by dividing weight (kg) by squared 
height (m2). 
3.3.5 Body Composition 
Body composition was measured at each time point using a tetra polar (ankle-foot) lying multiple frequency 
bio-impedance analysis (BIA) device (Impedimed SFB7, Carlsbad, California, United States of America). 
Measurements were taken prior to placement of intravenous (IV) tube, and after the participant was lying down in 
resting position for 5 minutes. Participants were to remove all jewelry, metal objects and shoes. A user manual was 
developed by the research team to be followed in order to reduce measurement bias (Appendix D1). Fat free mass, fat 
mass, intracellular water, and extracellular water, were recorded into the participant database and expressed in kg, % of 
body weight, and kg/m2 (FFMI and FMI). FFM index was compared to reference values by Gonzalez et al that were 
adapted from Kyle et al’s cut offs [89] (Appendix E). FFM- and FM-index were calculated via the following equations: 
FFMI = FFM (kg) ÷ (height (m)2) 
FMI = FM (kg) ÷ (height (m)2) 
3.3.6 Muscle Strength and Physical Function 
Muscle strength was measured using hand grip dynamometry (JAMAR plus+, JAMAR, Hatfield, United States 
of America) at each time point using the non-dominant arm at 90 degrees; measurements were taken three times with 
standardised encouragement by the administer to provide a maximum and average score in kilograms; all three attempts 
were recorded. A user manual was developed for investigators to follow to reduce measurement bias (Appendix D2). 
Participant scores were compared to age- and gender specific reference values developed from 406 older subjects (283 
females, mean age 76.6 years) based on the European Working Group for Sarcopenia in Older People’s (EWGSOP) 
definition of sarcopenia [40].  
Physical function was assessed using a 6-minute walking test (6MWT) performed by a trained administer at 
each time point. The 6MWT was performed on a flat, straight surface, 20 meters in length with standardised 
encouragement given at each minute. Blood pressure was measured prior to commencing the 6MWT to ensure the 
participant was fit to participate. Oxygen saturation and heart rate were measured using a ChoiceMMed sats monitor 
(ChoiceMMed Germany, Düsseldorf, Germany) and perceived exertion was measured using the revised category-ratio 
Borg scale every minute [90]. Limiting factors of the walking test reported by the participant were also recorded post 
completion. If the participant chose not to participate in the 6MWT, a 4-meter walking test was conducted (4MWT). 
For this test, the investigator measured 4 meters on a flat, straight surface and would record the time it took for the 
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participant to walk this distance meters as fast as possible. Physical function was assessed by gait speed (m/s) and 
compared to age- and gender specific reference values developed from 406 older subjects (283 females, mean age 76.6 
years) based on the European Working Group for Sarcopenia in Older People’s definition of sarcopenia [22]. Gait speed 
was calculated via the following equations: 
6MWT: distance (m) ÷ 360 seconds (6 minutes) = gait speed (m/s) 
4MWT: 4 meters ÷ time (seconds) = gait speed (m/s) 
 
3.3.7 Definition of Sarcopenia  
 
Participants were defined as presarcopenic, sarcopenic, or severely sarcopenic based on the definition 
recommended by the EWGSOP [22]. Sarcopenia was based on muscle mass (FFMI), muscle strength and physical 
function combined (Table 1). Sarcopenic obesity was defined if participants were classed as sarcopenic, with a FMI 
above the age- and gender specific reference cut off (Appendix E).  
Table 1 Conceptual stages for sarcopenia [22] 
Stage Muscle mass Muscle strength Physical function 
Presarcopenia ¯   
Sarcopenia ¯ ¯ Or ¯ 
Severe sarcopenia ¯ ¯ ¯ 
 
3.3.8 Malnutrition Status  
 
At each time point, malnutrition status of each participant was evaluated using the Malnutrition Screening Tool 
(MST) [91] and Scored Patient-Generated Subjective Global Assessment (PG-SGA) [92] tools by either an Accredited 
Practicing Dietitian or student dietitian. Each question on each tool was asked by the research investigator to give a 
numerical and categorical rating of malnutrition for the participant. The MST questionnaire gives a numerical score of 
from 0 - 4, 0 being no risk of malnutrition, and 4 indicating highest risk. The Scored PG-SGA gives an overall global 
assessment categorised into three ratings; A: well-nourished, B: mild to moderately malnourished, and C: severely 
malnourished. The Scored PG-SGA also gives a continuous numerical score from 0 to 55 which aids in calculating the 
global assessment; where a higher score indicates worse malnutrition signs and symptoms, and a score of 9 or more (7 
or more in older adults) indicated critical need for dietetic intervention [93]. 
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3.3.9 Physical Activity, Quality of Life and Dietary Recall  
 
Participants completed a series of questionnaires at each time point in the study to assess their current physical 
activity levels, dietary intake, and quality of life.  
Independent physical activity was measured using the Godin-Shepard Leisure-Time Physical Activity 
Questionnaire [94] to produce a numerical score of physical activity levels based on the amount of strenuous, moderate, 
or light exercise the participant part takes in over the previous week.  
Quality of life was assessed using the EORTC QLQ-C30 questionnaire [95] which the participant completes 
prior to any other assessments, appointments, or treatments in order to produce an accurate score. The EORTC QLQ-
C30 questionnaire is broken into five functioning scales (physical, role, emotional, cognitive, and social), three 
symptom scales (pain, nausea/vomiting, and fatigue), six single-item scales (dyspnea, sleep disturbances, appetite loss, 
constipation, diarrhea, and financial), and a global QOL assessment. Using an excel spreadsheet, participant’s raw 
scores were appropriately transformed to a linear scale (0-100) where the higher score represents a higher functional 
level, or higher level of symptoms. Transformed scores were recorded into the de-identified database. Participant scores 
were compared to the European reference values for the EORTC QLQ-C30 as these reference values represent a 
general population reference for QOL in cancer patients [96]. 
Dietary protein and energy intake was determined using the five-pass dietary recall methodology to record a 
“typical” day of dietary intake of one weekday and weekend day. Energy and protein intake was assessed using the 
Xyris software in Foodworks ™ or Easy Diet Diary ™ programs. Dietary energy and protein intake analysed in the 
Xyris software was compared to the recommended protein and energy requirements based on NEMO guidelines of 
³125kJ/kg (adjusted) body weight, and ³1.2g protein/ kg (adjusted) body weight for adults undergoing chemotherapy 
[75].  
 
3.3.10 Data Analysis  
 
This study was a convenience sample. To gain a well-rounded representation of this group, we aimed to recruit 
at least 45 eligible participants. This number was derived from the prevalence of sarcopenia in BC which is estimated to 
range from 25% [24] to 58% [97]. Using an average prevalence of sarcopenia of 40% and a potential dropout rate of 
20%, 45 participants was required to be able to identify 15 participants with sarcopenia. This sample size would allow 
for comparisons to be drawn between groups and time points, and to investigate correlations between body composition 
and physical function.  
Recruitment returned a small convenience sample, which influenced the initial data analysis plan. As only 5 
participants have been included for baseline data, no normality testing was performed, and descriptive statistics were 
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presented as median and range (continuous), or by a number (categorical). Although recruitment returned a small 
number of participants, a data analysis plan has been outlined for further recruitment and is detailed below.  
For future analysis, normally distributed continuous variables (age, height, weight, BMI) will be described by 
mean and standard deviation (not-normally distributed: median and IQR), while categorical variables (gender, stage of 
disease, use of oral steroids, independent exercise, ethnicity) will be described by number and percentage of total. 
Normality is tested using a Shapiro-Wilk test on continuous baseline and outcome variables. Continuous outcome 
variables (body composition, muscle strength, physical function, dietary intake, physical exercise, EORTC-QLQ-C30) 
will be analysed using a paired t-test between baseline and week 3, baseline and week 6, and week 3 and week 6. A 
paired t-test was chosen over a repeated-measures ANOVA as this testing requires no missing data points. Confounding 
variables of age, protein intake, and independent exercise will be tested using linear or logistic regression in the case of 
exceeding 20 participants. Associations between muscle strength and other variables will be analysed through a 
Pearson’s correlation test. All data points will be taken into account, and in patients who dropped out, their data until 
attrition will be included in analysis. 
 
3.4 Results 
 
Within the preliminary 5-month recruitment time frame from November 2017 to March 2018, 10 women with 
primary metastatic BC were approached to participate in the study. Of these women, 5 were recruited for participation, 
2 declined due to no desire to participate, and 3 were ineligible due to English being of second language, and having 
already surpassed C1D1 of their treatment (Figure 1). 
Baseline characteristics are outlined in Table 2. The median age of participants was 62 years (range 47 - 76 
years). At baseline, 4 of the 5 participants were categorized as well nourished, and 1 as moderately malnourished using 
the PGSGA malnutrition tool. Protein and energy intakes were insufficient in 3 participants. The median BMI of 
participants at baseline was 27kg/m2; 3 participants were classified as overweight (n=2) or obese (n=1) while the 
remaining 2 were within the healthy weight range (BMI = 18.5-24.9). No participants were classified as sarcopenic at 
baseline based on their FFMI and physical function, or muscle strength. The Godin-Shepard Time Leisure question 
reflected that 4 participants did not engage in sufficient physical activity at baseline.  
The QOL transformed global, and physical function scores from the EORTC QLQ-C30 questionnaire on 
baseline, week 3, and week 6 are displayed in Table 3. At baseline, the median QOL global score was 58.3 (ranging 
from 16.7 – 100), while the median physical function score was 73.3 (ranging from 60 – 80). Both median global QOL 
and physical function scores at baseline were above the median reference values (50 and 60 respectively) for women 
with BC stages III-IV.   
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Three subjects completed the study (Table 3). The first subject was a 70-year-old Caucasian female 
undergoing daily oral chemotherapy (Capecitabine). Although she was obese (BMI of 33.3kg/m2), her FFM-index did 
not indicate sarcopenia. No significant changes were recorded in weight, body composition between baseline and week 
3; due to equipment malfunctions, body composition could not be recorded on the final week 6 visit. The subject had a 
normal hand-grip strength and physical function a relatively high fat mass and insufficient physical activity. Global 
QOL for this subject decreased over time, however she was above the reference value for global QOL.  
The second subject was a 62-year-old Asian female undergoing weekly IV chemotherapy (taxane-based). 
While FFMI, muscle strength, and physical function did not indicate sarcopenia, a BMI of 24.5 indicated normal 
weight. This subject had no significant changes in muscle strength, physical function, insufficient physical activity or 
weight over the 6 weeks, however her FFM-index dropped by 2kg/m2 between baseline and week 3 but remained fairly 
stable between week 3 and week 6. FFMI did not fall below the minimal reference value for this subject. QOL remained 
stable at all time points, however was below the reference value.  
The third subject was a 47-year-old Caucasian female undergoing IV chemotherapy (taxane-based) 3 weeks 
on, 1 week off. Physical function and muscle strength were normal, and there were no significant changes in weight or 
FFMI over time. FFMI, muscle strength and physical function did not indicate sarcopenia. At week 6, the participant’s 
physical function decreased below the reference cut-off value. Physical activity was sufficient at baseline and week 3, 
however dropped significantly at week 6. QOL increased at the final time point, however was still below the reference 
value.  
 
Table 2 Demographics and clinical characteristics of participants with metastatic breast cancer (n=5) 
Characteristic N  
Age (years), median (range) 62.2 (47 – 76) 
Ethnicity   
Caucasian 3  
Asian 1  
Pacific Islander 1  
 
Smoking Status  
Yes 0 
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No 5  
Treatment Pathway   
Oral 1  
Intravenous  4  
Chemotherapy Agents  
Taxane 2  
Anthracycline 2  
Capectabine 1  
 
 
Table 3 Body composition, handgrip strength, physical function, sarcopenia and malnutrition scores 
of patients with metastatic breast cancer undergoing chemotherapy at baseline (n = 5) 
Characteristic Median Range  
Height (m) 1.63 1.58 – 1.67 
Weight (kg) 72 61.0 – 92.7 
BMI (kg/m2) 27 22.8 – 33.3 
FFM-index (kg/m2) 18.74 15.4 – 20.4 
FM-index (kg/m2) 8.1 5.4 - .7 
Sarcopenia (n)  0   
Handgrip Strength (kg) 25.6 18.7 – 32.4 
Handgrip Strength (n below r.v. for sarcopenia) 0  
Physical Function (m/s) 1.1 0.97 – 1.3 
Protein intake (% of requirement) 75% 40 - 115 
MST score 1 0 - 2 
0 (n) 3   
1 (n) 0   
2 (n) 2   
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Table 4 Descriptive and physical characteristics on three time points of chemotherapy in subjects/patients 
with metastatic breast cancer (n=3) 
 
Parameters Baseline Week 3 Week 6 Reference Values (rv) 
Mean+SD 
Global QOL score (% 
of rv) 
    
BOP_01 100 83.3 66.72 58.2 + (25.6) 
BOP_02 33.3 33.3 33.3 62.2 + (24.4) 
BOP_03 16.7 16.71 33.32 61.3 + (24.5) 
PF QOL score (% of 
rv) 
    
BOP_01 60 66.7 73.32 69.5 + (23.9) 
BOP_02 73.3 46.7 73.3 76.9 + (21.6) 
BOP_03 73.3 801 93.32 81.1 + (19) 
Weight (kg)     
BOP_01 92.7 92.7 92.42  
BOP_02 68.3 68.2 67.8  
BOP_03 60.9 60.91 61.52  
FFMI kg/m2 (% of rv)     
> 15 
 
BOP_01 20.4 (136%) 20.5 (137%)   
BOP_02 19.1 (127%) 17.1 (114%) 17.4 (116%)  
BOP_03 15.4 (103%) 15.6 (104%)1 16.2 (108%) 2  
FMI kg/m2    < 11.8 
BOP_01 12.7  12.8    
BOP_02 5.4  7.4  7   
BOP_03 7.3  7.2 1 6.82   
Muscle Strength kg 
(% of r.v.) 
    
 
 
BOP_01 28.7 (136%) 28.2 (134%) 31.72 (151%) > 21 kg 
PG-SGA A (n, %) 4   
PG-SGA B (n, %) 1   
PG-SGA C (n, %)  0   
PG-SGA numerical score 6 2 - 12 
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BOP_02 21.3 (123%) 24.9 (144%) 26.3 (152%) > 17.3 kg 
BOP_03 26.8 (158%) 23.71 (139%) 28.92 (170%) > 17 
Exercise Score      
> 24 
 
BOP_01 8 26 182  
BOP_02 5 9 6  
BOP_03 54 521 142  
Sarcopenia (y/n)     
BOP_01 no no n/a  
BOP_02 no no no  
BOP_03 no no no  
 
 
 
 
Figure 2 Change in physical function (m/s) over time 
 
 
3.5 Discussion 
 
Preliminary findings from this study have shown that in our small sample size (n = 5), there was no evident 
sarcopenia, a low rate (n = 1) of malnutrition, and a high rate (n = 3) of overweight and obesity. Muscle strength 
remained stable in the participants (n = 3) that completed the study, while physical function declined over the duration 
of the study in 2 participants. Insufficient protein intake and physical activity were noted in 4 out of 5 of the participants 
at baseline. For two of three subjects that completed the study, global quality of life scores were below reference cut-
offs for the entire duration of the study, however, their physical function scores were within reference cut-offs at all 
time points, except one time point for subject 2. Subject 1’s global quality of life score decreased, whilst their physical 
function score increased over the duration of the study; both scores, despite changing, remained within reference cut-
offs.  
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 Initiation of this pilot study was due to the limited range of research available exploring body composition, 
physical function, and muscle strength in patients with metastatic BC undergoing chemotherapy, creating a demand for 
evidence-based guidelines aimed at this population group. Although results from this study are preliminary, low 
physical activity levels and inadequate levels of protein intake highlighted within the study population are indicative of 
the lack of exercise and dietary protein. At present, online resources available for Australian patients with metastatic 
BC encourages “regular light exercise such as walking, swimming or gardening” and “a healthy balanced diet from the 
5 core food groups” with no specific recommendations regarding the amount of exercise and dietary energy, protein 
other nutrients or foods [98].   
While conclusions from research investigating early stage (I – III) BC populations cannot be directly 
transferred to the metastatic BC population, these studies have highlighted the importance of body composition’s 
influence on outcomes of disease [25-27, 41]. Knowing that nutrition (in particular protein intake) and exercise 
influence body composition (particularly FFM and FM), it is concerning for participants in our preliminary sample 
population as they are mostly overweight or obese and exhibit lifestyle factors that are precursors to developing 
sarcopenia (poor protein consumption and low physical activity). As highlighted in Prado et al’s work, sarcopenic 
obesity was an independent predictor of survival in cancer patients, irrespective of age, sex and functional status [43].  
The negative outcomes of sarcopenia have been extensively researched in cancer populations, and its 
associations with chemotherapy toxicity and treatment failure are well known [41, 42]. Exercise interventions in early 
stage BC populations, and other cancer populations highlight the benefits that exercise (particularly resistance training) 
can have on muscle mass, and therefore treatment outcomes, making a strong case for investigations to begin exercise 
interventions in metastatic BC populations [53-55]. Our study sample reflects the norm regarding physical in-activity in 
both cancer and healthy populations; Yang et al’s study reported that 76% of 114 early-stage bowel, breast or prostate 
cancer patients did not meet the recommended 150 minutes of exercise per week [52], while a 2014 study investigating 
exercise barriers in 27 patients with BC highlighted both internal and external barriers such as valuing other activities 
over exercise, and treatment side-effects [58]. It would be useful for future studies involving metastatic BC populations 
to investigate barriers and enablers of physical activity, as well as involving exercise-monitoring devices to measure 
true physical activity levels; these outcomes may will provide a more accurate representation of physical activity in this 
group, and insights into perceptions of exercise.  
Our study had several limitations, the first being a small sample size meaning we were unable to reach power, 
and unable to reflect true incidence of sarcopenia in this population. The small number of enrolled participants reflects 
the challenges that come with recruiting a strict inclusion criteria, in a restricted recruitment phase of 5 months. Our 
sample was restricted to patients with metastatic BC beginning a new cycle of chemotherapy treatment so that baseline 
measurements could begin on day one of the new cycle. This restriction made it difficult to recruit participants, and 
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further studies may choose to consider including participants who are at different stages of their first chemotherapy 
cycle for recruitment purposes. Further limitations regarding our small preliminary sample size meant that we were 
unable to use our own population sample as reference cut-offs for FFMI, and FFM as recommended by the EWGSOP 
[22].  Secondly, our study was limited with the follow-up time frame of 6 weeks; greater body compositional shifts 
would likely be more evident after a longer time period. This limitation will be overcome in future recruitment of the 
study with follow-up extended to at least 6 months. Plans for further recruitment for this study are in place to gain a 
greater understanding of the disease burden in this population to assess whether future lifestyle interventions are 
appropriate considering potential physical and social burden from participation. 
 
3.6 Conclusion  
 
Treatment goals for metastatic BC are palliative and focus on maintaining quality of life, prolonging life, and 
reducing treatment associated symptoms and pain [4], however, there is limited research that is aimed at improving 
current care nutrition and exercise guidelines for the metastatic BC population. With the ever-changing outcomes and 
survivorship for the metastatic BC population, evidence-based guidelines which are aimed at providing care that will 
enhance the remainder of their lives is a pressing task. Preliminary results from this study have found that this 
population face similar challenges to patients with early-stage BC of, insufficient physical activity, insufficient protein 
intake, and overweight and obesity, however no sarcopenia was identified. Additional findings from this study past 
preliminary results will give further insight into the prevalence of sarcopenia in this group and influence future 
intervention studies. Future observational studies may find value in investigating nutrition and exercise knowledge of 
the metastatic BC population as well as associated barriers and enablers to exercise. Investigating knowledge, barriers 
and enablers will give researchers a better understanding of how to structure intervention studies in this population 
group looking forward.  
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PART 4.0 Conclusions and Recommendations 
 
 
This thesis highlights gaps in current literature regarding the effects of chemotherapy on body 
composition, physical function, and muscle strength in patients with metastatic BC, and emphasises the 
importance of moving forward to create evidence-based guidelines for this population (Parts 1 & 2). 
Extensive literature exploring these outcomes in early stage (I-III) BC has informed practice to improve 
treatment outcomes, and overall survival in this group, however the metastatic population has received 
minimal research attention perhaps due to the increased burden for metastatic disease.  
The main goals for treatment in this population are to maintain quality of life, prolong life, and 
reduce treatment associated symptoms. Treatments for metastatic BC are ever-improving, leading to greater 
life expectancy in this population. With this in mind, it is important that health professionals are providing 
care that is able to support quality of life and reduce symptoms during this time. Investigating the changes in 
body composition, physical function, and muscle strength in this population is an important step towards 
creating guidelines that is able to enrich the remainder of the lives in these patients.  
 Part 3 of this thesis contains the complete research manuscript addressing the original research 
question: “Is there a change in body composition, physical function, and muscle strength in patients with 
metastatic BC between baseline, week 3 and week 6 of chemotherapy?”. The design of the study was set up 
specifically in response to this research question. Unfortunately, due to a low sample size, the research 
question was not able to be answered with significance. Although power was not reached with the sample 
size, normal body composition according to gender- specific reference cut-offs, and stable physical function 
and muscle strength in participants were recorded. While we didn’t see a reduction in these three outcomes 
as hypothesised, findings involving “insufficient” physical activity and poor protein intake amongst majority 
of the sample size indicate risk of developing sarcopenia/sarcopenic obesity. 
Limitations to this study design (addressed in detail in section 3.5) include the restricted five-month 
recruitment phase, six-week follow up, and having body composition measurements through BIA alone. This 
research study has future plans of continuation, whereby these limitations will be addressed through 
continuing recruitment, and following up patient body composition with routine CT scans 6 months post 
baseline.   
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With limitations to the study, and preliminary results in mind, recommendations for future research 
investigating body compositional, physical function, and muscle strength changes in the metastatic BC 
population during chemotherapy can be made to improve knowledge to influence future intervention studies. 
Further investigations into this population group may consider exploring barriers and enablers to physical 
activity, as well as objectively recording physical activity levels through a device over questionnaires to give 
more accurate results. Investigating participant’s knowledge of appropriate nutrition and exercise for their 
disease will also further our understanding of what resources should be supplied to this population.  
Looking forward, further observational studies on nutrition and exercise interventions are required to 
inform intervention studies in order to provide evidence-based practice guidelines for women with metastatic 
BC.  
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Appendix A: Literature Summary Matrix Table 
 
Theme Outcomes of sarcopenia/ 
low fat free mass in patients with cancer 
Exercise interventions in patients with 
cancer and/or sarcopenia 
Nutrition supplementation to 
improve FFM, physical function, 
or muscle strength 
Combined nutrition and exercise 
interventions to improve FFM, 
physical function, or muscle 
strength 
Prado, 
2009 [24] 
- n=127 prospective study from 2002-
2005 
- Sarcopenia was a significant predictor of 
toxicity and TTP regardless of age, 
performance status and albumin 
- Toxicity and TTP was significantly 
higher in sarcopenic patients than non-
sarcopenic (62 d vs. 105 d respectively) 
   
Taffe,  
2006 [37] 
 - Review article on exercise treatment for 
sarcopenia  
- 12 weeks of HIT in older men showed 
an 11.4% increase in muscle cross 
sectional area of mid-thigh, and >100% 
increase in muscle strength 
- RTE is an effective countermeasure for 
sarcopenia 
- RTE 1 – 2 times per week is sufficient 
for improvement in sarcopenia 
- Aerobic activity has negligible effects on 
augmenting muscle mass and strength 
opposed to resistance 
 
  
Yoshimura
, 2017 [55] 
 - Systematic review including 7 RCTs (4 
exercise) 
- Very low-quality evidence suggests that 
exercise interventions may improve 
muscle mass, muscle strength, and 
- Systematic review of 7 RCTs (5 
nutrition) 
- Very low-quality evidence 
suggests nutritional interventions of 
EAA, collagen peptide, protein, and 
- Systematic review of 7 RCTs (4 
combination of nutrition (protein or 
EAA) and exercise)  
- Studies included 2 – 3 times a week 
of comprehensive training 
 44 
walking speed after 3 months of 
intervention 
- Exercise interventions should contain 
resistance exercise 
tea catechin may be effective in 
improving muscle strength after 3 
months of intervention 
- HMB, leucine, BCAA, vitamin D 
and creatine were also potentially 
beneficial 
- Low-quality evidence suggests that 
combined intervention of exercise 
and nutrition may have positive 
effects in improving walking speed 
after 3 months  
- No significant effects on FFM, 
muscle strength or maximum 
walking speed 
 
Carneiro, 
2016 [45] 
- 14 studies investigating sarcopenic 
obesity  
- Sarcopenic obesity is associated with 
worse clinical outcomes (mortality) 
- Prevalence of sarcopenic obesity in 
cancer: 1 – 29% 
- Sarcopenic obesity associated with 
higher risks of DLT (how much higher) 
and  
in sarcopenic colorectal cancer with a 
fivefold higher prevalence of major post-
operative complications than non-
sarcopenic, although another study found 
no associations in colorectal cancer  
- 1 study: 47% of sarcopenic obese 
participants had worse functional status 
than non-sarcopenic obese participants 
- 1 study: sarcopenic obesity, but not 
sarcopenia or obesity alone was an 
independent predictor of shorter survival 
in patients with pancreatic cancer  
 
   
Mochamat
, 2017 [63] 
  - Systematic review (n=21) 
compared treatment with or without 
vitamin, mineral, protein or dietary 
supplements in cancer cachexia 
- Vitamin D: improvement in 
muscle weakness in prostate cancer 
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- Vitamin C: improvement in 
several QOL domains in terminal 
cancer  
- Vitamin E and Omega-3 FA: 
showed effects on survival 
- 1 study: patients gained average 
of 2kg body weight with HMB, 
arginine, and glutamine 
supplementation 
- 1 study: 470 patients with cancer 
supplemented with HMB, arginine, 
and glutamine supplementation 
found no significant increases to 
FFM after 8 weeks, but a strong 
trend in the direction of FFM 
increase was noted 
- Carnitine supplementation in 
patients with advanced pancreatic 
cancer gained weight with an 
average of 3% increase in BMI and 
improved overall survival 
 
Knols, 
2015 [47] 
 - Systematic review (n=34) RCTs and 
controlled clinical trials assessed for PE 
improving PF and psychological well-
being in patients with cancer 
- Patients with cancer in specific 
populations may benefit from PE during 
and after treatment 
- QOL and longevity benefits from PE in 
patients with cancer may vary with 
disease stage, treatment & lifestyle 
- Patients with breast, colorectal, and 
prostate cancer who are overweight found 
to have increased cancer recurrence and 
poorer survival 
- PE interventions alone are not sufficient 
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to influence weight significantly in 
overweight patients with cancer during 
medical treatment  
- Self-reported QOL improved in the PE 
intervention groups in most studies 
reviewed 
 
 
  
Abbreviations: 
TTP Time to Tumour Progression 
DLT Dose Limiting Toxicity 
EAA Essential Amino Acids  
BCAA Branched Chain Amino Acids 
QOL Quality of Life  
RCT Randomised Control Trial 
FFM Fat Free Mass 
 
BMI Body Mass Index 
HMB Beta-Hydroxy-Beta-Methylbutyrate 
PE Physical Exercise 
PF Physical Functioning  
RTE Resistance Training Exercise 
HIT High Intensity Training 
FA        Fatty Acid 
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Appendix B: Project Timeline  
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Appendix C: Ethical Clearance and Approval Letters 
 
 
The following pages provide the official letter confirming ethical clearance for the BOP study by the Mater 
Misericordiae Ltd Human Research Ethics Committee.  
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Appendix D1: Developed BIA User Manual 
 
 
i) BIA user manual: Developed by Amelia Bandera in collaboration with BOP study 
research team 
 
 
Bioelectrical Impedance (BIA) 
Impedimed BIS 
User manual 
 
 
Populations not suitable for this measure: 
- Pregnant women 
- Patients with a pacemaker 
 
What do you need?  
• Impedimed suitcase 
• Pen 
• Piece of paper 
• Scales 
• Stadiometer 
• Impedimed SFB7 set (stored in second drawer of filing cabinet), charged 
 
Instructions: 
 
• Check the battery status on the display 
o Choose SETUP button to see battery 
 
Step 1: Calibration 
• Calibrate the device before use 
o One a day is sufficient 
 
1. Remove clips from leads and connect the leads to the calibration test cell 
according to the colour-coding 
2. Switch ‘on’ the machine using the small white button on the front 
3. On the main screen, press the “test” button 
4. Press the “start” button to make a test reading (you will see a “calculating” 
screen and after that, a “passed” screen signifies the device and leads are in 
a good condition) 
5. De-attach the leads from the calibration device and re-attach the clips 
 
Step 2: Prepare your patient 
 
1. Measure and record height and weight  
2. Record patient’s DOB, URN and age 
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3. Make sure the patient has emptied their bladder before the test 
4. Have the patient take off their right shoe and sock (if applicable) 
5. Ask patient to remove any jewellery, metal on the body or metal in clothes 
(e.g. belt, coins in wallet) 
6. Position the patient on the bed with the right side of the body towards you 
(use left side in case the subject has an IV in the left arm)  
 
7. The legs should be apart, making sure to not touch each other. If needed, 
place a pillow in between the legs.  
8. Instruct the patient to rest for at least 5 minutes  
9. Clean the skin of the wrist, hand, ankle and foot with an alcohol wipe 
10. Place electrodes on the skin of the wrist, hand, ankle and foot  
 
 
 
 
11. Make sure the electrodes are 5 cm apart  
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12. Attach an alligator clip to each of the probe ends of the four leads 
13. Use the alligator clips to connect each lead to the tab portion of the electrode 
 
 
 
 
14. Apply leads according to the colour code (YELLOW = right wrist; RED = 
surface of right hand; BLUE = right foot on the ankle; BLACK = dorsal surface 
of right foot). 
15. Press firmly to attach each colour coded lead plug to the similar colour locking 
socket on the device one by one. 
16. Go back to main menu and click on MEASURE 
17. Insert URN as file name and click ‘edit’ at the ‘patient details’ box 
18. Enter gender, height, age and weight in this screen 
19. Press OK 
 
Step 3: Measure 
 
1. Press MEASURE 
2. Check electrode placement as suggested on screen 
3. Press START 
4. Record the results 
5. Clean the leads of the device with a detergent wipe. For patients under 
contact precautions (the dark green signs) wipe over with the disinfectant 
wipe twice. Allow it to dry in between.  
6. Use reference values to interpret the results 
 
 
Yello
w 
Black 
Blue 
Red 
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Appendix D2: Developed JAMAR PLUS User Manual 
 
 
 
JAMAR PLUS+ user manual: Developed by Amelia Bandera, and reviewed by Dr Barbara van 
der Meij 
 
 
JAMAR PLUS+  
User Manual 
 
What you need: 
• JAMAR PLUS+ (Stored in 3rd drawer in filing cabinet) 
• Pen 
• Paper 
• 2 x AAA batteries (if needing recharging); batteries are replaced on the back of the device  
 
Instructions: 
 
1. Check the patient’s grip on the JAMAR PLUS+ before commencing: If the patient has 
smaller-average sized hands, adjust the grip position of the JAMAR PLUS+ to the 2nd 
lowest rung; if the patient has average-large sized hands, move the grip of the JAMAR 
PLUS+ to the 3rd lowest rung. To remove the grip position, push the lower end of the 
handle so that the slotted portion rotates away from the lower shaft. Allow it to then 
separate from the top shaft. Choose the preferred position and replace the top part of the 
handle onto the chosen rung, then rotate the lower part of the handle back onto the shaft 
until it clicks into place. 
 
2. Use the “on/off” button to turn the JAMAR PLUS+ device on. 
 
3. Check that the units of measurement is in kg rather than lbs. This can be seen on the right 
side of the display. If lbs is highlighted, remove the battery cover on the back of the device. There 
is a switch under the cover where you can switch lbs to kg. 
 
4. Use the patient’s left hand for the test: To select the hand and mode of the test, press the 
button “select test” until only the “L” is shown in the top left corner on the display. 
 
5. The patient will perform 3 tests for an average score. To choose the number of tests the 
patient will complete, press the button “# of trials” until the number “3” is highlighted on the top of 
the display. 
 
6. To begin the test, ask the patient to hold the JAMAR PLUS+ in their left hand while seated. 
Their left arm should be at a 90 degree angle. 
 
7. Have the patient grasp the JAMAR PLUS+ gently to that the palm fits comfortably to the 
rear of the instrument 
 
8. Press the “start” key and the number “1” will appear and flash at the top of the display. 
 
9. Give the patient encouragement to squeeze the grip as hard as they can. Record the 
reading on the display 
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10. Give the patient 30 seconds recovery and press “test” to repeat for the second, and then 
third tests. 
 
11. Be sure to record each reading for all 3 tests and transfer measurements to data sheet with 
patients de-identified number 
 
12. Press the “reset” key to clear the previous settings before moving to the next patient to take 
measures. 
 
13. When finished using the JAMAR PLUS+, use the “on/off” button to turn off.  
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Appendix E: Diagnosis of Sarcopenia: Measureable Reference Cut-Off Values [22] 
 
Criterion Measurement 
Method 
Gender specific cut-off points Reference group defined Reference  
 
Low fat-
free mass 
 
BIA 
 
≤15.0 kg/m2 
 
 
Based on hospital admission patients (n 
= 816 females) compared to gender-, 
age- and height matched healthy 
volunteers (n = 1707)  
 
 
[89] 
High fat 
mass 
BIA  
≥11.8 kg/m2 
 
Based on hospital admission patients (n 
= 816 females) compared to gender-, 
age- and height matched healthy 
volunteers (n = 1707) 
[89] 
Muscle 
Strength 
Hand-grip 
strength  
BMI ≤ 23 ≤ 17 kg 
BMI 23.1–26 ≤ 17.3 kg 
BMI 26.1–29 ≤ 18 kg 
BMI > 29 ≤ 21 kg 
 
Based on quartiles of study group (n = 
5,317) 
[99] 
Physical 
Function 
Gait speed (m/s)  Height ≤ 159 cm ≥ 7 s (GS < 0.65 
m/s) 
 Height > 159 cm ≥ 6 s (GS < 0.76 
m/s) 
 
Based on quartiles of study group (n = 
5,317) 
[99] 
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